Company intelligence / Profile preview

Boost Biopharma, Inc.

Woburn, Massachusetts, United Statesboostbiopharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Boost Biopharma is entering clinical phase testing of its first next-generation SARS-CoV‑2 protein vaccine for both intramuscular and nasal administration. Preclinical studies have shown strong immunogenicity relative to mRNA vaccines. The company has also developed monoclonal antibodies effective against a wide range of SARS-CoV‑2 variants in preclinical testing. It is supported by CEPI and NIH/NIAID as it transitions from preclinical development into human trials.[3][6]

Therapeutic areas: Infectious Diseases
Modalities: Recombinant protein vaccinesMonoclonal antibodies (mAbs)Protein subunit vaccines[6][5]
Industry: Biotech

Partnerships

US National Institutes of Health / NIAID [6]Coalition for Epidemic Preparedness Innovations (CEPI) [3][6]

Beyond the preview

Go deeper on Boost Biopharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boost Biopharma, Inc..

Explore the full profile